Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€54.00

€54.00

3.850%
2.0
3.850%
€71.78
 
18:01 / Tradegate WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Cytokinetics

sharewise wants to provide you with the best news and tools for Cytokinetics, so we directly link to the best financial data sources.

News

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market: https://cdn.content.foolcdn.com/images/1umn9qeh/production/782b0b9f4f412d891de6f8f7670abc6b1a621e10-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly